🚨 New Podcast Alert! Deep Margin brings you the latest in Head & Neck Oncology, hosted by IReC Deputy Director Dr Ben O’Leary and Oncologist Dr Will Ince. 👉 Listen now: https://t.co/19URqWc96I #CancerResearch #OncologyPodcast #DeepMargin

🔔The 16th Royal Marsden Head and Neck Conference is upcoming on 27/11/25, with a focus on Oropharyngeal Cancer. Details here:

Double, double, toil & trials! 🧪 Our team at The Royal Marsden are brewing up cutting-edge research to tackle recurrent head & neck cancer. Happy Halloween from IReC! 🎃🧬

🗓️ Tomorrow, 4th October 2025, marks the first-ever Salivary Gland Cancer Day, raising awareness of this rare disease. The 2025 theme highlights the power of unity in creating positive change. Spread the word! #SGCDay #SalivaryGlandCancerDay

🗓️ Tomorrow, 4th October 2025, marks the first-ever Salivary Gland Cancer Day, raising awareness of this rare disease. The 2025 theme highlights the power of unity in creating positive change. Spread the word! #SGCDay #SalivaryGlandCancerDay

Next is the recently completed national head and neck robotic surgery audit! This project for the first time reported the scope of UK HN robotic surgical practice, in addition to reporting post-operative outcomes. Keep an eye out for the resulting article in the coming months!

The first audit by the 2023-2025 committees was the Head & Neck MDT Snapshot Audit, which investigated UK MDT's adherence to national guidelines and cancer targets in HNSCC. The project produced 2 BAHNO presentations and 2 peer reviewed publications, with more on the way!

REMINDER! TYPHOON has officially opened! Interested in taking part in collaborative research? Gain points on applications and contribute to a multi-centre study assessing post-tonsillectomy bleeding. More information is available on our website https://t.co/fadBCqo91S

There are just a couple of days left to apply to the INTEGRATE 2025-2027 committees! More information is available on the INTEGRATE website below! Applications close this Friday (15/08/2025). https://t.co/jSlQk8q3wF

There is just over one week to apply to the INTEGRATE 2025-2027 committees! More information is available on the INTEGRATE website below! Applications close on 15/08/2025. https://t.co/jSlQk8q3wF

🤖🤖🤖 The follow-up window for the national head and neck is now closed! Thank you to the over 30 UK centres that participated! Keep an eye on your emails over the next few weeks for a final update of patient recruitment and audit certificates! 🤖🤖🤖

Applications are still open for the INTEGRATE 2025-2027 committees! More information is available on the INTEGRATE website below! https://t.co/jSlQk8q3wF

🤖🤖🤖 The follow-up period for the national head and neck robotic audit closes in two weeks today! Thank you to all of our collaborators for participating in this project, the final deadline for data submission is 04/08/2025! 🤖🤖🤖

💥New combined updated long-term analysis from RTOG 9501 + EORTC 22931 published this week in @Annals_Oncology @myESMO Median follow-up 7 years 💢Survival benefit from postop CRT may be not limited to patients with HNSCC positive margins or ENE (highlighted in figure) ⁉️Should

Applications are now open for the INTEGRATE 2025-2027 committees! Multiple opportunities are available including Chair, Secretary, and members of our Otology, Rhinology, and HN committees! More information is available on the INTEGRATE website! https://t.co/jSlQk8pvH7

🤖🤖🤖 The head and neck robotic surgery audit recruitment window is now closed. Thank you to all who have taken part, we have over 300 patients submitted from over 30 centres! We now enter the final follow-up phase, which closes on 04/08/2025! 🤖🤖🤖

We are delighted to announce that as of this morning, the national head and neck robotic surgery audit has over 300 patients submitted! Thank you to all of our collaborators, @ENT_UK and @BAHNOOfficial for your support with this project!

Quite the week for head&neck unit @royalmarsdenNHS 3 major outputs. https://t.co/XAt1b2pP6v in @NEJM with Kevin Harrington https://t.co/AlMrph4Uj5 ION in @TheLancet Kate Newbold @DrChrisNutting and @IReC_RM consensus https://t.co/t2SOdlRkvB in @JNCI_Now ThankYou collaborators

In the KEYNOTE-689 phase 3 trial, the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved event-free survival among participants with locally advanced head and neck cancer without affecting surgical outcomes. Full trial results: https://t.co/O1lGRH5vJu

Original Article: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (KEYNOTE-689 phase 3 trial) https://t.co/O1lGRH5vJu Editorial: Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer https://t.co/KvTys4ESQE #Oncology